Clifford Chance advised Zak?ady Farmaceutyczne “Polpharma” S.A. on the deal, while Norton Rose Fulbright advised a consortium of financial institutions. The transaction involved a term and revolving…
Polpharma’s USD210.9 Million Revolving Facility Agreement
